FDA grants orphan drug status to DKN-01 for certain gastrointestinal cancers

The FDA granted orphan drug designation to DKN-01 for the treatment of gastric or gastroesophageal junction cancers.DKN-01 (Leap Therapeutics) is a humanized monoclonal antibody that blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling.“Orphan drug designation for DKN-01 in gastric and gastroesophageal junction cancer is another significant milestone in our DKN-01 development program and underscores the need for new treatment options for these indications,” Douglas E. Onsi, president and CEO of Leap Therapeutics, said in a company-issuedRead More

Share on facebook
Share on twitter
Share on linkedin